Skip to content

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

Non-invasive MR Imaging Diagnosis of Transplant Rejection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02006108
Enrollment
21
Registered
2013-12-09
Start date
2012-11-27
Completion date
2017-04-11
Last updated
2018-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant Rejection

Keywords

kidney, transplant, rejection, Feraheme, ferumoxytol

Brief summary

The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a renal allograft on Ferumoxytol-MRI demonstrates significant differences between rejected and non-rejected transplants.

Detailed description

In children with kidney transplants, immunologically mediated rejection is the major cause of allograft failure. Thus, the therapeutic success of kidney transplants is highly dependent on the ability to avoid rejection during both the acute and chronic phase after transplantation. Children with kidney transplants currently undergo at least three routine (protocol) biopsies during the first two years after the transplantation in addition to biopsies required to investigate deterioration of kidney function. These biopsies are invasive and nearly always require general anesthesia, causing anxiety and distress of the patients and their parents, as well as significant costs to our health care system. There is currently no non-invasive diagnostic tool capable of detecting rejection in vivo. Thus, the goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The investigators propose to accomplish this goal by detecting macrophage infiltration in kidney transplants with iron oxide nanoparticle-enhanced MR imaging. Macrophages play a major role in transplant rejection. CD68-positive macrophages comprise approximately 50% of the infiltrating leukocyte population in renal allograft rejection, they co-localize with areas of tissue-damage and fibrosis, and are preponderant in more severe forms of rejection. The investigators hypothesize that iron oxide nanoparticle-enhanced MR imaging can detect differences in macrophage infiltrations in renal allografts undergoing rejection as opposed to allografts without significant rejection. This hypothesis is based on the bio-physical properties of intravenously injected superparamagnetic iron oxide nanoparticles, which are phagocytosed by tissue macrophages and cause strong signal effects on MR images. The specific aims of the study are the following: Aim #1. Technical Development of a Quantitative Susceptibility Mapping (QSM)-Sequence for in vivo MRI detection and quantification of iron oxide nanoparticle-labeled macrophages.This aim will focus on the technical development of Quantitative Susceptibility Mapping (QSM), a novel MR imaging pulse sequence that will be used to accurately quantify the tissue concentration of free ferumoxytol and ferumoxytol in macrophages in renal allografts. Based on pulse sequence optimizations of phantoms with known concentrations of free and cell-bound iron, we expect to generate accurate estimates of tissue iron concentrations and macrophages with the QSM-MRI method. Aim #2. Detect rejection in kidney allografts with ferumoxytol-enhanced MRI. The investigators hypothesize that ferumoxytol can detect and quantify macrophages in kidney allografts, based upon the observation that iron oxide nanoparticles can be taken up by macrophages in malignant tumors. The investigators will evaluate the ability of ferumoxytol to map macrophage quantities in renal allografts, with histopathological correlation. We expect significantly higher ferumoxytol-MRI enhancement and macrophage quantities in rejected allografts compared to non-rejected allografts.

Interventions

Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging

OTHERMRI-GE Healthcare 3 Tesla magnet

All patients will undergo

Sponsors

Lucile Packard Children's Hospital
CollaboratorOTHER
Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Completed solid organ transplant with referral for transplant follow-up

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Radiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* Maps24 hours to 7 daysAccording to the study hypothesis, macrophage infiltration into rejected kidneys will be significantly greater than in healthy kidneys; since macrophages are expected to phagocytose injected iron, there should be a detectable difference in signal intensity between healthy and rejected organs. This can be evaluated using semiquantitative T2\* maps.

Secondary

MeasureTime frameDescription
Correlation of Cell-bound Iron Quantities on QSM Sequences With Macrophage and Iron Stains on Histopathology3 weeksTo evaluate our ability to quantify cell-bound iron using the novel QSM sequence, we use histopathological data showing 1) the iron content of renal tissue sampled, and 2) the level of macrophage infiltration of the renal tissue. We will perform iron and macrophage stains in biopsy tissues in order to determine this.

Countries

United States

Participant flow

Participants by arm

ArmCount
Feraheme
Intravenous injection of Feraheme, 5 mg Fe/kg Interventions: Drug: Feraheme Procedure: MR Scan Feraheme: Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging MRI-GE Healthcare 3 Tesla magnet: All patients will undergo
21
Total21

Baseline characteristics

CharacteristicFeraheme
Age, Categorical
<=18 years
14 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
Age, Continuous17.8 years
STANDARD_DEVIATION 2.8
Drug allergies, specifically against iron compounds0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
12 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
GFR
Normal
90 ml/min/1.73 m2
STANDARD_DEVIATION 29
GFR
Rejection
52 ml/min/1.73 m2
STANDARD_DEVIATION 24
MRI Compatibility21 Participants
Number of Patients with Kidney Transplant21 Participants
Pregnancy0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
3 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
15 Participants
Region of Enrollment
United States
21 participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 21
other
Total, other adverse events
0 / 21
serious
Total, serious adverse events
0 / 21

Outcome results

Primary

Radiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* Maps

According to the study hypothesis, macrophage infiltration into rejected kidneys will be significantly greater than in healthy kidneys; since macrophages are expected to phagocytose injected iron, there should be a detectable difference in signal intensity between healthy and rejected organs. This can be evaluated using semiquantitative T2\* maps.

Time frame: 24 hours to 7 days

Population: T2\* value of transplant kidney

ArmMeasureGroupValue (MEAN)Dispersion
FerahemeRadiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* MapsNo Rejection23.3 ms (delayed postcontrast scans)Standard Deviation 5.4
FerahemeRadiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* MapsRejection31.1 ms (delayed postcontrast scans)Standard Deviation 14.4
Secondary

Correlation of Cell-bound Iron Quantities on QSM Sequences With Macrophage and Iron Stains on Histopathology

To evaluate our ability to quantify cell-bound iron using the novel QSM sequence, we use histopathological data showing 1) the iron content of renal tissue sampled, and 2) the level of macrophage infiltration of the renal tissue. We will perform iron and macrophage stains in biopsy tissues in order to determine this.

Time frame: 3 weeks

Population: CD163 positive macrophages

ArmMeasureValue (NUMBER)
FerahemeCorrelation of Cell-bound Iron Quantities on QSM Sequences With Macrophage and Iron Stains on Histopathology0 correlation coefficient

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026